Coronary artery disease Circulatory System Chronic ischaemic heart disease
Conditions
Interventions
Perindopril 8 mg per day (4 mg for patients aged 70 or older) or placebo for approximately 4 years treatment, follow-up at 3 months, 6 months and every 6 months thereafter.
Sponsors
Institut de Recherches Internationales Servier (France)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 years or more, both genders 2. Stable documented coronary artery disease 3. Not scheduled for revascularisation
Exclusion criteria
Exclusion criteria: 1. Clinical signs of heart failure requiring treatment with an angiotensin converting enzyme (ACE) inhibitor 2. Uncontrolled treated hypertension 3. Clinically significant obstructive valvular disease 4. Hypertrophic cardiomyopathy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite endpoint of cardiovascular mortality, non-fatal myocardial infarction and cardiac arrest resuscitation, measured at 3 months, 6 months and every 6 months thereafter | — |
Secondary
| Measure | Time frame |
|---|---|
| Composite endpoints of mortality, non-fatal acute myocardial infarction, unstable angina and cardiac arrest resuscitation and individual endpoints, measured at 3 months, 6 months and every 6 months thereafter | — |
Countries
Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Slovakia, Spain, Sweden, Switzerland, Turkey, United Kingdom
Outcome results
None listed